Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Korea's Medical Tourism Push Can Benefit Korean And Global Pharma - Medical Korea 2011

This article was originally published in PharmAsia News

Executive Summary

SEOUL - South Korea's bid to top Thailand, India and Singapore as an Asian hub for healthcare services, particularly medical tourism, should be beneficial to both Korean and global pharmas, Seoul officials said

You may also be interested in...



United Arab Emirates Officials Check Korea's Healthcare Infrastructure To Support Medical Tourism MOU

SEOUL - In a follow-up to a memorandum of understanding signed in March to draw medical tourists to South Korea, feasibility study officials from the Ministry of Health of the United Arab Emirates and Abu Dhabi Health Authority visited Korea June 26-30

United Arab Emirates Officials Check Korea's Healthcare Infrastructure To Support Medical Tourism MOU

SEOUL - In a follow-up to a memorandum of understanding signed in March to draw medical tourists to South Korea, feasibility study officials from the Ministry of Health of the United Arab Emirates and Abu Dhabi Health Authority visited Korea June 26-30

Seoul Seeks To Expand Biomedical Fund With MOUs Signed With U.S. States Massachusetts And Maryland

SEOUL - The Seoul Metropolitan Government is pushing to expand its KRW 100 billion ($92.2 million) biomedical fund, established last year by the Boston venture capital firm Oxford Bioscience Partners and Korea's Hanwha Venture Capital to boost Korea's life sciences industries

Related Content

UsernamePublicRestriction

Register

SC077704

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel